Cytotoxic studies of paclitaxel (Taxol®) in human tumour cell lines

Journal article

This article aims to review the literature on studies supporting using Taxus sumatrana (Miq.) de Laub (Cemara Sumatra) as a cancer treatment. The method involved a literature review using the keywords "Taxus sumatrana" and chemical compound or pharmacological activity. There are no reports of pharmacological activity related to cancer from extracts or parts of the T. sumatrana plant. Despite a lack of scientific evidence supporting its anticancer activity, T. sumatrana is widely used to treat cancer traditionally. So, further research is needed to validate using T. sumatrana as a cancer treatment. Pharmacodynamic studies are necessary to demonstrate its mechanism of action. Additionally, toxicity studies are needed to determine the safety, ensuring no toxic effects on normal cells. Further research is also required to evaluate the effectiveness of T. sumatrana in clinical cancer treatment. In conclusion, T. sumatrana promises to be a natural medicine for cancer treatment. However, its validated use as a cancer treatment requires adequate supporting data scientifically

Authors: Liebmann, JE; Cook, JA; Lipschultz, C; Teague, D; Fisher, J

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Springer Nature [academic journals on nature.com]
• Journal: British Journal of Cancer
• Volume: 68
• Issue: 6
• Pages: 1104-1109
• Publication date: 1993-12-01
• DOI: 10.1038/bjc.1993.488
• EISSN: 1532-1827
• ISSN: 0007-0920
• Language: English
• Keywords: Toxicity; Pharmacology; Clonogenic assay; In vitro; Internal medicine; Chemistry; Cytotoxicity; Cytotoxic T cell; Chemotherapy; Medicine; Biology; Cell culture; Biochemistry; Paclitaxel; Drug